Adam W Bartlett1, Pagakrong Lumbiganon2, Thahira A Jamal Mohamed3, Keswadee Lapphra4, Dina Muktiarti5, Quy Tuan Du6, Rawiwan Hansudewechakul7, Penh Sun Ly8, Khanh Huu Truong6, Lam Van Nguyen9, Thanyawee Puthanakit10,11, Tavitiya Sudjaritruk12, Kulkanya Chokephaibulkit4, Viet Chau Do13, Nagalingeswaran Kumarasamy14, Nik Khairulddin Nik Yusoff15, Nia Kurniati5, Moy Siew Fong16, Dewi Kumara Wati17, Revathy Nallusamy18, Annette H Sohn19, Azar Kariminia1. 1. The Kirby Institute, UNSW Australia, Sydney, Australia. 2. Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 3. Pediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. 4. Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 5. Cipto Mangunkusumo-Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia. 6. Children's Hospital 1, Ho Chi Minh City, Vietnam. 7. Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. 8. National Centre for HIV/AIDS, Dermatology and STDs, Phnom Penh, Cambodia. 9. National Hospital of Pediatrics, Hanoi, Vietnam. 10. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 11. Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 12. Department of Pediatrics, Faculty of Medicine, and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. 13. Children's Hospital 2, Ho Chi Minh City, Vietnam. 14. Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India. 15. Hospital Raja Perempuan Zainab II, Kelantan, Malaysia. 16. Hospital Likas, Kota Kinabalu, Malaysia. 17. Sanglah Hospital, Udayana University, Bali, Indonesia. 18. Penang Hospital, Penang, Malaysia. 19. TREAT Asia/amfAR, The Foundation for AIDS Research, Bangkok, Thailand.
Abstract
BACKGROUND: Perinatally HIV-infected adolescents (PHIVA) are an expanding population vulnerable to loss to follow-up (LTFU). Understanding the epidemiology and factors for LTFU is complicated by varying LTFU definitions. SETTING: Asian regional cohort incorporating 16 pediatric HIV services across 6 countries. METHODS: Data from PHIVA (aged 10-19 years) who received combination antiretroviral therapy 2007-2016 were used to analyze LTFU through (1) an International epidemiology Databases to Evaluate AIDS (IeDEA) method that determined LTFU as >90 days late for an estimated next scheduled appointment without returning to care and (2) the absence of patient-level data for >365 days before the last data transfer from clinic sites. Descriptive analyses and competing-risk survival and regression analyses were used to evaluate LTFU epidemiology and associated factors when analyzed using each method. RESULTS: Of 3509 included PHIVA, 275 (7.8%) met IeDEA and 149 (4.3%) met 365-day absence LTFU criteria. Cumulative incidence of LTFU was 19.9% and 11.8% using IeDEA and 365-day absence criteria, respectively. Risk factors for LTFU across both criteria included the following: age at combination antiretroviral therapy initiation <5 years compared with age ≥5 years, rural clinic settings compared with urban clinic settings, and high viral loads compared with undetectable viral loads. Age 10-14 years compared with age 15-19 years was another risk factor identified using 365-day absence criteria but not IeDEA LTFU criteria. CONCLUSIONS: Between 12% and 20% of PHIVA were determined LTFU with treatment fatigue and rural treatment settings consistent risk factors. Better tracking of adolescents is required to provide a definitive understanding of LTFU and optimize evidence-based models of care.
BACKGROUND: Perinatally HIV-infected adolescents (PHIVA) are an expanding population vulnerable to loss to follow-up (LTFU). Understanding the epidemiology and factors for LTFU is complicated by varying LTFU definitions. SETTING: Asian regional cohort incorporating 16 pediatric HIV services across 6 countries. METHODS: Data from PHIVA (aged 10-19 years) who received combination antiretroviral therapy 2007-2016 were used to analyze LTFU through (1) an International epidemiology Databases to Evaluate AIDS (IeDEA) method that determined LTFU as >90 days late for an estimated next scheduled appointment without returning to care and (2) the absence of patient-level data for >365 days before the last data transfer from clinic sites. Descriptive analyses and competing-risk survival and regression analyses were used to evaluate LTFU epidemiology and associated factors when analyzed using each method. RESULTS: Of 3509 included PHIVA, 275 (7.8%) met IeDEA and 149 (4.3%) met 365-day absence LTFU criteria. Cumulative incidence of LTFU was 19.9% and 11.8% using IeDEA and 365-day absence criteria, respectively. Risk factors for LTFU across both criteria included the following: age at combination antiretroviral therapy initiation <5 years compared with age ≥5 years, rural clinic settings compared with urban clinic settings, and high viral loads compared with undetectable viral loads. Age 10-14 years compared with age 15-19 years was another risk factor identified using 365-day absence criteria but not IeDEA LTFU criteria. CONCLUSIONS: Between 12% and 20% of PHIVA were determined LTFU with treatment fatigue and rural treatment settings consistent risk factors. Better tracking of adolescents is required to provide a definitive understanding of LTFU and optimize evidence-based models of care.
Authors: Barbara Castelnuovo; Frank Mubiru; Shadia Nakalema; Adelline Twimukye; Agnes Kiragga Journal: Int Health Date: 2018-07-01 Impact factor: 2.473
Authors: S Nimkar; C Valvi; D Kadam; B B Rewari; A Kinikar; N Gupte; N Suryavanshi; A Deluca; A Shankar; J Golub; R Bollinger; A Gupta; I Marbaniang; V Mave Journal: HIV Med Date: 2018-03-24 Impact factor: 3.180
Authors: Amy L Slogrove; Michael Schomaker; Mary-Ann Davies; Paige Williams; Suna Balkan; Jihane Ben-Farhat; Nancy Calles; Kulkanya Chokephaibulkit; Charlotte Duff; Tanoh François Eboua; Adeodata Kekitiinwa-Rukyalekere; Nicola Maxwell; Jorge Pinto; George Seage; Chloe A Teasdale; Sebastian Wanless; Josiane Warszawski; Kara Wools-Kaloustian; Marcel Yotebieng; Venessa Timmerman; Intira J Collins; Ruth Goodall; Colette Smith; Kunjal Patel; Mary Paul; Diana Gibb; Rachel Vreeman; Elaine J Abrams; Rohan Hazra; Russell Van Dyke; Linda-Gail Bekker; Lynne Mofenson; Marissa Vicari; Shaffiq Essajee; Martina Penazzato; Gabriel Anabwani; Edith Q Mohapi; Peter N Kazembe; Makhosazana Hlatshwayo; Mwita Lumumba; Tessa Goetghebuer; Claire Thorne; Luisa Galli; Annemarie van Rossum; Carlo Giaquinto; Magdalena Marczynska; Laura Marques; Filipa Prata; Luminita Ene; Liubov Okhonskaia; Pablo Rojo; Claudia Fortuny; Lars Naver; Christoph Rudin; Sophie Le Coeur; Alla Volokha; Vanessa Rouzier; Regina Succi; Annette Sohn; Azar Kariminia; Andrew Edmonds; Patricia Lelo; Samuel Ayaya; Patricia Ongwen; Laura F Jefferys; Sam Phiri; Mwangelwa Mubiana-Mbewe; Shobna Sawry; Lorna Renner; Mariam Sylla; Mark J Abzug; Myron Levin; James Oleske; Miriam Chernoff; Shirley Traite; Murli Purswani; Ellen G Chadwick; Ali Judd; Valériane Leroy Journal: PLoS Med Date: 2018-03-01 Impact factor: 11.069
Authors: Jonathan Izudi; John Mugenyi; Mary Mugabekazi; Benjamin Muwanika; Victor Tumukunde Spector; Andrew Katawera; Adeodata Kekitiinwa Journal: Biomed Res Int Date: 2018-05-06 Impact factor: 3.411
Authors: Andrew F Auld; Simon G Agolory; Ray W Shiraishi; Fred Wabwire-Mangen; Gideon Kwesigabo; Modest Mulenga; Sebastian Hachizovu; Emeka Asadu; Moise Zanga Tuho; Virginie Ettiegne-Traore; Francisco Mbofana; Velephi Okello; Charles Azih; Julie A Denison; Sharon Tsui; Olivier Koole; Harrison Kamiru; Harriet Nuwagaba-Biribonwoha; Charity Alfredo; Kebba Jobarteh; Solomon Odafe; Dennis Onotu; Kunomboa A Ekra; Joseph S Kouakou; Peter Ehrenkranz; George Bicego; Kwasi Torpey; Ya Diul Mukadi; Eric van Praag; Joris Menten; Timothy Mastro; Carol Dukes Hamilton; Mahesh Swaminathan; E Kainne Dokubo; Andrew L Baughman; Thomas Spira; Robert Colebunders; David Bangsberg; Richard Marlink; Aaron Zee; Jonathan Kaplan; Tedd V Ellerbrock Journal: MMWR Morb Mortal Wkly Rep Date: 2014-11-28 Impact factor: 17.586
Authors: Andreas D Haas; Elizabeth Zaniewski; Nanina Anderegg; Nathan Ford; Matthew P Fox; Michael Vinikoor; François Dabis; Denis Nash; Jean d'Amour Sinayobye; Thêodore Niyongabo; Aristophane Tanon; Armel Poda; Adebola A Adedimeji; Andrew Edmonds; Mary-Ann Davies; Matthias Egger Journal: J Int AIDS Soc Date: 2018-02 Impact factor: 5.396